UNSPSC 51372605: Ciramadol hydrochloride

This classification denotes the hydrochloride form of an opioid receptor agonist with the molecular formula C15H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9NQ109OW0G, chemically known as phenol, 3-((r)-(dimethylamino)((1r,2r)-2-hydroxycyclohexyl)methyl)- but more generally known as ciramadol, which bears US NIH Compound Identifier 44463. European Medicines Agency schedules Ciramadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07477MIG.

UNSPSC 51372605 Ciramadol hydrochloride is a Commodity code that nominally covers a specific pharmaceutical active ingredient, but recent state and local solicitations tagged under this code do not target ciramadol itself. Instead, the code appears in procurement notices for naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local governments use this code family to solicit pharmaceutical products and pharmacy benefit services, including emergency response medications, generic drug sourcing through cooperative purchasing vehicles, and strategic procurement initiatives to improve drug distribution efficiency and cost management. The issuing bodies range from county health departments and state health and human services commissions to multistate cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Department of Administration (administering MMCAP) represent the geographic and institutional spread in recent activity.

Recent opportunities show Seminole County, Florida posting an IFB on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the county community health building and a response deadline of July 26, 2026. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at establishing direct contracting relationships outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026, with a March 26, 2026, response deadline to establish multiple contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local government facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026. The code shows activity concentrated in the South and Upper Midwest, with cooperative purchasing and direct-to-manufacturer models emerging as strategic procurement approaches alongside traditional county health supply contracting.